BR112013014198A2 - composições compreendendo um inibidor de pi3k e um inibidor de mek e seu uso para o tratamento de câncer - Google Patents

composições compreendendo um inibidor de pi3k e um inibidor de mek e seu uso para o tratamento de câncer

Info

Publication number
BR112013014198A2
BR112013014198A2 BR112013014198A BR112013014198A BR112013014198A2 BR 112013014198 A2 BR112013014198 A2 BR 112013014198A2 BR 112013014198 A BR112013014198 A BR 112013014198A BR 112013014198 A BR112013014198 A BR 112013014198A BR 112013014198 A2 BR112013014198 A2 BR 112013014198A2
Authority
BR
Brazil
Prior art keywords
inhibitor
compositions
treating cancer
pi3k
mek
Prior art date
Application number
BR112013014198A
Other languages
English (en)
Inventor
Carlos Garcia-Escheverria
Janet Anne Meurer Ogden
Jianguo Ma
Laurent Debussche
Loic Vicent
Stuart Mcmillan
Original Assignee
Merck Patent Gmbh
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013014198(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh, Sanofi Sa filed Critical Merck Patent Gmbh
Publication of BR112013014198A2 publication Critical patent/BR112013014198A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013014198A 2010-12-09 2011-12-08 composições compreendendo um inibidor de pi3k e um inibidor de mek e seu uso para o tratamento de câncer BR112013014198A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42146510P 2010-12-09 2010-12-09
US201161436258P 2011-01-26 2011-01-26
US201161467485P 2011-03-25 2011-03-25
FR1159940 2011-11-03
PCT/US2011/063871 WO2012078832A1 (en) 2010-12-09 2011-12-08 Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer

Publications (1)

Publication Number Publication Date
BR112013014198A2 true BR112013014198A2 (pt) 2016-09-13

Family

ID=45464841

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013014198A BR112013014198A2 (pt) 2010-12-09 2011-12-08 composições compreendendo um inibidor de pi3k e um inibidor de mek e seu uso para o tratamento de câncer

Country Status (22)

Country Link
US (1) US20140024653A1 (pt)
EP (1) EP2648729A1 (pt)
JP (1) JP2013544892A (pt)
KR (1) KR20140011311A (pt)
CN (1) CN103402518A (pt)
AR (1) AR084216A1 (pt)
AU (1) AU2011338354A1 (pt)
BR (1) BR112013014198A2 (pt)
CA (1) CA2820748A1 (pt)
CL (1) CL2013001643A1 (pt)
CR (1) CR20130246A (pt)
DO (1) DOP2013000131A (pt)
MA (1) MA34815B1 (pt)
MX (1) MX2013006319A (pt)
NZ (1) NZ611581A (pt)
PE (1) PE20140702A1 (pt)
RU (1) RU2013131241A (pt)
SG (1) SG190368A1 (pt)
TW (1) TW201306837A (pt)
UY (1) UY33790A (pt)
WO (1) WO2012078832A1 (pt)
ZA (1) ZA201303687B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013243429A1 (en) * 2012-04-06 2014-10-23 Merck Patent Gmbh Methods for treating cancer using PI3K inhibitor and MEK inhibitor
CN104703655A (zh) * 2012-10-11 2015-06-10 默克专利股份公司 具有抗-癌活性的6-氧代-1,6-二氢-哒嗪衍生物与mek抑制剂的组合
ES2945387T3 (es) 2014-02-07 2023-06-30 Verastem Inc Procedimientos y composiciones para tratar el crecimiento celular anormal
WO2016014390A1 (en) * 2014-07-25 2016-01-28 Merck Patent Gmbh Compositions and methods for mek inhibitor combination therapy in the treatment of cancer
BR112020012388A2 (pt) * 2017-12-22 2020-11-24 Adienne S.A. método para a determinação in vitro da potência de um ligante anti-cd26
JP2022547358A (ja) 2019-09-13 2022-11-14 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
AU2021361138A1 (en) * 2020-10-16 2023-06-08 Memorial Sloan Kettering Cancer Center Induction of ferroptosis for cancer therapy
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Also Published As

Publication number Publication date
JP2013544892A (ja) 2013-12-19
CN103402518A (zh) 2013-11-20
EP2648729A1 (en) 2013-10-16
AR084216A1 (es) 2013-05-02
CL2013001643A1 (es) 2014-03-28
NZ611581A (en) 2015-02-27
UY33790A (es) 2012-07-31
TW201306837A (zh) 2013-02-16
DOP2013000131A (es) 2013-11-15
KR20140011311A (ko) 2014-01-28
ZA201303687B (en) 2014-01-29
SG190368A1 (en) 2013-06-28
RU2013131241A (ru) 2015-01-20
WO2012078832A1 (en) 2012-06-14
PE20140702A1 (es) 2014-06-26
CR20130246A (es) 2013-09-03
CA2820748A1 (en) 2012-06-14
US20140024653A1 (en) 2014-01-23
AU2011338354A1 (en) 2013-06-27
MA34815B1 (fr) 2014-01-02
MX2013006319A (es) 2013-07-03

Similar Documents

Publication Publication Date Title
BR112013033940A2 (pt) terapia combinada compreendendo um inibidor de cdk4/6 e um inibidor de pi3k para uso no tratamento de câncer
BR112013014198A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de mek e seu uso para o tratamento de câncer
SMT201600430B (it) Inibitori di chinasi e loro uso nel trattamento del cancro
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
CO6801796A2 (es) Composiciones de tratamiento de pozo de liberación retardada para uso en fluídos de tratamiento de pozo
CO6900118A2 (es) Métodos para tratar el cancer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
BR112012030927A2 (pt) fosfaplatinas e seu uso para o tratamento de cânceres
BR112012004970A2 (pt) inibidores de jak2 e seu uso para o tratamento de doenças mieloproliferativas e câncer
BR112014014558A8 (pt) composição farmacêutica, uso de um antagonista de crth2 e de um inibidor de bomba de prótons, e, kit para o tratamento de esofagite eosinofílica
BRPI0908854A2 (pt) composições e métodos para o tratamento de tumor de origem hematopoética
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI0906444A2 (pt) Compostos de 4-piridinona e seu uso para câncer
IL225442A0 (en) Preparations containing rankl suppressors and their uses for the prevention and treatment of cancer
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BR112014004937A2 (pt) método para tratar e/ou prevenir um câncer dependente de ligante de ahr natural e inibidor de ahr
BRPI0907931A2 (pt) Derivado de pirrolopirimidina como inibidor de pi3k e uso do mesmo
CL2013001324A1 (es) Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer.
BR112015006512A2 (pt) composição para tratar tecidos biológicos danificados
BR112013032360A2 (pt) compostos inibidores de glioblastoma e seu uso
BR112014004297A2 (pt) compostos para uso em reforço da coagulação
HK1183486A1 (zh) 三環類 和/或 抑制劑
BR112012003209A2 (pt) composições e métodos para tratar infecção fúngica da unha
BRPI0919857A2 (pt) tratamentos para cancer com radiacao e imunocitocinas
BR112012000614A2 (pt) métodos e composições para o tratamento de condições médicas relacionadas a tireóide com folatos reduzidos
CO6910192A2 (es) Composiciones y métodos para tratar el cáncer usando el inhibidor de pi3kbeta y el inhibidor de la vía de map, incluídos los inhibidores de mek y raf

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]